Bank of New Hampshire Decreases Stake in Amgen Inc. (NASDAQ:AMGN)

Bank of New Hampshire cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 8.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,391 shares of the medical research company’s stock after selling 122 shares during the quarter. Bank of New Hampshire’s holdings in Amgen were worth $433,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the business. Miracle Mile Advisors LLC boosted its stake in shares of Amgen by 46.1% in the first quarter. Miracle Mile Advisors LLC now owns 8,791 shares of the medical research company’s stock valued at $2,739,000 after buying an additional 2,775 shares in the last quarter. Patriot Financial Group Insurance Agency LLC raised its holdings in Amgen by 1.4% during the first quarter. Patriot Financial Group Insurance Agency LLC now owns 4,442 shares of the medical research company’s stock worth $1,384,000 after purchasing an additional 60 shares during the last quarter. Charter Oak Capital Management LLC acquired a new position in Amgen during the first quarter worth $223,000. Wedmont Private Capital raised its holdings in Amgen by 10.7% during the first quarter. Wedmont Private Capital now owns 7,545 shares of the medical research company’s stock worth $2,158,000 after purchasing an additional 731 shares during the last quarter. Finally, Perennial Advisors LLC raised its holdings in Amgen by 2.8% during the first quarter. Perennial Advisors LLC now owns 19,671 shares of the medical research company’s stock worth $6,128,000 after purchasing an additional 530 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 1,500 shares of the company’s stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the sale, the senior vice president now owns 8,162 shares of the company’s stock, valued at $2,364,368.16. This represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.76% of the stock is owned by company insiders.

Amgen Stock Performance

Amgen stock opened at $290.33 on Monday. The stock has a fifty day moving average price of $281.57 and a 200 day moving average price of $285.39. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The firm has a market capitalization of $156.11 billion, a P/E ratio of 38.45, a PEG ratio of 2.63 and a beta of 0.51.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The firm had revenue of $8.15 billion during the quarter, compared to the consensus estimate of $8.05 billion. During the same quarter in the previous year, the business earned $3.96 earnings per share. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on AMGN. Royal Bank of Canada reduced their price objective on Amgen from $324.00 to $320.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. UBS Group reaffirmed a “neutral” rating and set a $315.00 price objective (down from $319.00) on shares of Amgen in a report on Friday, May 2nd. Bank of America lifted their price objective on Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a report on Wednesday, March 5th. Erste Group Bank cut Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. Finally, Mizuho lifted their price objective on Amgen from $235.00 to $280.00 and gave the stock a “neutral” rating in a report on Wednesday, May 7th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $309.22.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.